


Annual report 2021-2022

ABN 55 167 124 067











About the Academy

The Australian Academy of Health and Medical Sciences is the impartial, authoritative, cross-sector voice of health and medical science in Australia. We advance health and medical research in Australia and its translation into benefits for all, by fostering leadership within our sector, providing expert advice to decision makers, and engaging patients and the public.

We are an independent, interdisciplinary body of Fellows – elected by their peers for their outstanding achievements and exceptional contributions to health and medical science in Australia. Collectively, they are a representative and independent voice, through which we engage with the community, industry and governments.

The Academy is uniquely positioned to convene cross-sector stakeholders from across Australia to address the most pressing health challenges facing society. We focus on the development of future generations of health and medical researchers, on providing independent advice to government, and on providing a forum for discussion on progress in health and medical research with an emphasis on translation of research into practice.

The Academy is registered with the Australian Charities and Not-for-profits Commission (ACNC) and is endorsed as a deductible gift recipient.

ABN: 55 167 124 067

www.aahms.org

Acknowledgements

The Academy is most grateful for all gifts and donations given towards our charitable activities. We rely on funds from our Fellows and charitable donations, alongside our grant funding, to deliver our activities. We are most grateful to all the organisations who have supported our work through grants, sponsorships, donations and other contributions during the past year and in the past. We are especially grateful for the many hours of time and the considerable wisdom our Fellows, Associate Members and others give to the Academy's work.

We are grateful for the support of the University of Sydney and Queensland Government, who generously host the Academy's Sydney and Brisbane offices.

The Academy receives funding from the Australian Government. The views expressed in our reports/publications/activities do not necessarily reflect the views of the Australian Government.

The Academy acknowledges the traditional custodians of the land on which our offices stand and on which we hold our meetings and events across the country. Aboriginal and Torres Strait Islander peoples were the nation's first scientists, and they remain the spiritual and cultural custodians of their land. We pay our respects to elders past and present.

Contents

About the Academy	1
Acknowledgements	1
Academy strategy 2019-2022	3
President's report	4
CEO's report	6
Nuturing future research leaders	10
Influencing policy	13
Governance	16
Financials	20

Academy strategy 2019-2022

Our purpose

To advance health and medical research in Australia and its translation into benefits for all by fostering leadership within our sector, providing expert advice to decision makers, and engaging patients and the public.

Our vision

A future in which health and medical science, with the Academy as its champion, drives sustained improvement in the health of the Australian and global community.

Objectives

- Influence policy: Provide independent and research-based expert advice on challenges and opportunities in health, enabling decisions informed by the best available evidence.
- Nurture talented research leaders: Cultivate an environment in Australia in which
 future health and medical science leaders can thrive where they can represent the
 community in which we work.
- Celebrate excellence: Promote excellence in all we do, underpinned by an active Fellowship of Australia's best and brightest researchers, which can reflect the full diversity of health and medical sciences.
- Support Indigenous health and wellbeing: Strengthen our contribution to improving Indigenous health and wellbeing and the representation of researchers of Aboriginal and/or Torres Strait Islander descent.



President's report



The COVID-19 pandemic has created a new era – as we adjust to living and working in the "new normal", there is no doubt about the critical importance of health and medical research and innovation, as well as the need for impartial, expert, evidence-based advice for policymakers, industry and the wider community.

The COVID-19 pandemic has stretched for longer than many could have imagined, with the emergence of new variants creating new challenges over the past 12 months. Despite these

hurdles, I am proud to report that the Academy has continued to thrive and grow during these turbulent times, making a significant impact on the national health agenda. I thank each of you who has contributed to the Academy's achievements during this period. Your hard work and dedication are greatly appreciated.

Our 2021-22 annual report highlights the significant contributions of our Fellows and Associate Members. Major themes over the past year have focused on futureproofing health in Australia, with policy and engagement work focused on the health impacts of climate change, building data-enabled research excellence, and transforming healthcare by integrating research and innovation as core functions of the health system.

In addition, we have continued to engage with federal, state and territory governments on issues that affect the health and medical research and innovation sector, as well as the wider community. This has included providing submissions and responses to inquiries on issues including the Department of Health's primary healthcare 10-year plan, the Medical Research Future Fund (MRFF) draft strategy, and NHMRC consultations on gender equality.

We work closely with the four other Learned Academies, including in our role as a member of the Australian Council of Learned Academies (ACOLA), on several cross-cutting issues. This has included joint statements on COP26 and Australia's path to net-zero emissions, the ARC funding veto, support for the Uluru Statement from the Heart, and against the war in Ukraine. We also presented a joint submission on mitochondrial donation law reform and the development of a synthesis report between ACOLA, the Academies, and the Australian Research Data Commons (ARDC) on enabling Australia's data-enabled future. The spirit of collaboration and cooperation on these projects has resulted in stronger outcomes, and we sincerely thank our colleagues for their contributions to these collaborative efforts. I would particularly like to thank Professor Louisa Jorm for her excellent work in chairing the Health and Medical Data steering committee.

In April 2022, we released our statement on the health impacts of climate change, *Climate change: an urgent health priority*. This statement highlights how global warming is an unprecedented practical and ethical challenge to the health sector in Australia and globally. The associated risks to human health demand urgent action. The statement came after two years of work, including reviewing evidence and convening cross-sector discussions about the short-, medium- and long-term impacts of climate change on health. I am most grateful to Professor Warwick Anderson, Professor Tony Capon and Professor Fran Baum for leading the steering committee for this important project.

A well-defined, rapid, path to a net-zero world is needed to ensure the health and wellbeing of all Australians and, as an Academy, we will continue to support this endeavour and take steps to ensure we play our part.

We spoke out against harassment of Australian scientists, after it was reported that 1 in 5 Australian scientists has experienced threats after speaking to the media about COVID-19. We also released a statement supporting the Therapeutic Goods Administration and its staff, who have also been subject to harassment. While rigorous debate is nothing new in science, harassment is totally unacceptable. We will continue to stand with health professionals and researchers as they do their jobs, many going well and truly above and beyond leading the pandemic response.

On a brighter note, I am delighted to report that the Academy continues to support the next generation of research leaders, with 43 mentees joining our competitive flagship Mentorship Program in 2021-22. We look forward to their contributions to the Academy as Associate Members.

We have continued to host our popular Life as a Clinician-Scientist symposia, even as lockdowns in some states required a shift to online events. The hybrid of online and in-person events has resulted in some of our highest ever registrations, with our online Allied Health symposium attracting more than 400 registrations across Australia. The impact of these symposia on junior doctors, medical, science, allied health and nursing and midwifery students cannot be overstated - as they are inspired about the many pathways to a fascinating and rewarding career as a clinician-scientist. We will host more in-person events in 2023, including expansion even further across the country.

I wish to especially acknowledge the ongoing important contribution of the Academy's standing committees; their work is detailed in the governance section of this report. We are very grateful to these Fellows who commit their time to helping guide the Academy and assist us towards meeting our strategic goals. I thank the Executive and Council for the many hours they devote to Academy matters to ensure we steer a steady and visionary path.

This is my last President's Report as my three-year term draws to a close. It is safe to say that having started my term as the Academy's second President in October 2019, it has proven to be quite different to what anyone could have expected. However, the Academy's performance over the past three years has been far beyond any expectations, and that is a testament to the outstanding work, expertise, dedication and commitment of our Fellows and Associate Members. The importance of an Academy of Health and Medical Sciences during the pandemic has been crucial for the country and has informed Australia's exceptional response. I could not be more grateful for your support over the past three years, and I look forward to continuing to work with you in my capacity as Immediate Past President and as a Fellow, and to join with you in watching our relatively young Academy continue to blossom in its role leading health and medical sciences in our incredible country.

With my warmest wishes,

Sugued Scheffer

Professor Ingrid Scheffer AO FRS FAA PresAHMS

President 2019 - present

CEO's report



The past year has continued to bring substantial challenges, but as we move into a new stage of the pandemic, once again the importance of health and medical sciences is clear. I am, as always, immensely proud of the achievements of the Academy over the past 12 months, and in awe of the amazing work of our Fellows and Associate Members, who continue to contribute their considerable knowledge and expertise for the benefit of the nation.

The 2021-22 financial year has been an exciting and especially fruitful time for our policy projects. We published our statement on the health

impacts of climate change, which included commitments by the Academy to ensure we are doing our bit to address this important issue. We worked with ACOLA and the other Learned Academies to release cross-disciplinary reports on <u>Australia's data-enabled research future</u> for the Australian Research Data Commons (ARDC). Most significantly, we progressed our first major policy project, which will be published in October 2022, and outlines a vision for embedding research and innovation as core functions of the health system, for the benefit of health and healthcare in Australia. It brings together international and national evidence alongside contributions from more than 260 individuals across health, research and industry to compile the draft of our first flagship report. My thanks to all the Fellows, Associate Members and other individuals who have contributed their time so generously to our policy work over the past 12 months.

We also launched a new website, which allows us to better showcase our activities, as well as the full diversity of the Fellowship. We hope this website will be a useful resource for our Fellows, Associate Members and the wider research community.

Our strategic goal to nurture the next generation of health and medical researchers is one that we take seriously. Despite the restrictions associated with the pandemic, we were able to continue our work to inspire future clinician-scientists through <u>Life as a Clinician-Scientist</u> symposia held both online and in-person. The pandemic has only served to reinforce the important role played by this group. Our Mentorship Program continues to attract remarkable emerging research leaders, who gain mentorship and training opportunities, as well as the opportunity to contribute to Academy projects as Associate Members.

We were delighted to announce our inaugural recipient of the Academy Medal for Outstanding Female Researcher in October 2021 – Professor Georgina Long AO FAHMS, a truly deserving winner recognised for her transformative work advancing melanoma treatments and improving patient outcomes. We also awarded the Jian Zhou medal to two impressive rising stars in medical research – Professor Di Yu and Professor Sherene Loi FAHMS. I would like to congratulate all our impressive award recipients and encourage nominations of individuals who are deserving of recognition when the window opens in October.

Our secretariat staff have continued to work hard to increase the Academy's profile and help the Academy meet our goals to influence policy, celebrate excellence, nurture future research leaders and support Indigenous health and wellbeing – through policy and engagement, events, and communications. We welcomed Claire Vaz as our new Events and Program Manager in May 2022, and Policy Officer Emily Todd in June 2022, joining Policy Manager Lanika Mylvaganam, who was promoted to the role in March 2022. Margaret de Silva joined as Communication and Media Manager while Katie Rowney is on parental leave (until February

2023), while Dr Carla Muma leads our Fellowship and Award Coordination. The secretariat works incredibly hard and I cannot thank them enough for their support over the past 12 months. They bring considerable expertise in these areas to deliver the Academy's activities and engage with stakeholders in government, health, research and innovation.

I would also like to again thank Dr Cath Latham, who was the Interim CEO until October 2021 while I was on parental leave, for all her work in progressing the Academy's work.

Our Fellowship acts as an independent and expert voice, providing an invaluable resource for health and medical sciences in Australia, and while I do not know what lies ahead next year, I am confident that as the Academy grows, we will continue to make a significant impact on the national health, research and innovation agenda.

Thank you to Ingrid, the AAHMS Executive and Council members for their support and guidance throughout 2021-22, and all members of the Academy's committees and working groups. I wish to particularly thank Ingrid, as she concludes her term as President – it has been a challenging time and certainly not what we imagined your Presidency would look like when you assumed the role in October 2019. We have greatly appreciated your leadership, guidance and wisdom during these uncertain times.

As always, please do not hesitate to contact me or the secretariat if you have any questions about the Academy or our work.

All the best,

Catherine Luckin
Chief Executive Officer

athenhi

Celebrating excellence: our Fellowship

New Fellows



Academy Fellows are elected by their peers based on their outstanding achievements and exceptional contributions to health and medical science in Australia. They are a representative and independent voice, through which we engage with the community, industry and governments.

We were delighted to welcome 28 Ordinary Fellows and one Corresponding Fellow in October 2021:

- Professor Jerry Adams FAA FRS
- Professor Kaarin Anstey FASSA
- Professor Julie Bines
- Professor Suzanne Cory AC FAA FRS
- Professor Jodie Dodd
- Professor Pat Dudgeon
- Professor Jonathan Golledge
- Professor Ron Grunstein AM
- Professor Rebecca Guv
- Professor Rana Hinman
- Professor Harriet Hiscock
- Professor Kirsten Howard
- Professor David Huang
- Professor Christine Jenkins AM
- Professor Karin Leder

- Professor Louise Maple-Brown
- Professor Helen Marshall
- Professor Colette Mckav
- Professor Jodie McVernon
- Professor Alicia Oshlack
- Professor George Patton
- Professor Richard Price
- Professor Danny Rischin
- Professor Sir John Savill FRS
- Professor Kanta Subbarao
- Professor Penny Webb
- Professor Andrew Whitehouse
- Professor Ingrid Winship AO
- Professor Tien Wong (Corresponding Fellow)

Election process

In July 2021, 28 Ordinary Fellows were elected to the Fellowship in October 2021, following the process undertaken by selection committees and Council. This brings the Fellowship to over 400 Fellows – 448 in total, including 385 Ordinary, 11 Overseas, four Corresponding, 14 Honorary and 34 Retired Fellows.

Vale





Sadly, two Fellows passed in 2022. Emeritus Professor Pamela Russell AM FAHMS was a highly creative scientist whose contributions to oncology research gained international recognition and changed the lives of many. Professor Chris Del Mar AM FAHMS was a champion of evidence-based practice and much-loved mentor to many junior doctors and medical students. We send our condolences to the friends, families and colleagues of Professor Russell and Professor Del Mar.

Diversity and inclusion

The Academy continues to work towards its goals of greater diversity and inclusion within our Fellowship. Our <u>diversity and inclusion policy</u> outlines our commitment to diversity and inclusion and requires an annual report to Council on performance, including data from across the Academy's work, such as the selection of Fellows and Associate Members, committee membership, speakers at our events, and our secretariat. We encourage the nominations of Aboriginal and Torres Strait Islander candidates, and we are continually reviewing our election process to ensure we proactively address these issues at every stage.

- The proportion of women Fellows is increasing. In June 2022, we had 31% women (up from 29% last year), including 32% of all Ordinary Fellows (up from 30% last year).
- A record 68% of new Ordinary Fellows elected in October 2021 were women, up from 48% the previous year.
- Women are increasingly taking on leadership positions at the Academy, with gender parity on Council (50% women). Across the Academy's committees, 49% of members and 64% of chairs are women.
- The Academy had 43 Mentees in 2021-22- of these, 58% were women.
- In May 2022, the Academy launched a new website that is easier to use and on which important information is more accessible. We endeavour to represent the full diversity of the community in which we work through imagery and text across the website.
- We look to engage Indigenous suppliers, such as designers for our reports including for the design of our April 2021 statement, *Climate change: an urgent health priority*.
- We have endeavoured to consider accessibility in social media and digital work, including adding subtitles to video recordings and descriptions (alt text) on images.
- Diversity is also a priority when selecting media spokespeople and speakers at events.

Nuturing future research leaders

Life as a Clinician-Scientist

Despite restrictions in some states, the Academy continued to deliver online and - where possible - in-person events to bring current and aspiring clinician-scientists together to learn more about what it takes to succeed in a career that combines research and healthcare delivery.

Our Life as a Clinician-Scientist Victorian symposium was held in-person in July 2021 and was attended by more than 100 people. Due to COVID-19 restrictions, we held online events for New South Wales and Queensland in late 2021 and early 2022, both of which were well attended, despite flooding impacting parts of Brisbane in the lead-up to the symposium.

It has been an ambition for some time now to expand these events to new audiences. We were therefore delighted to hold two online symposia for allied health professionals and one for nurses and midwives, which were extremely popular. These events attracted more than 200 attendees in 2021, and our 2022 allied health event attracted more than 400 registrants – a LACS record, indicating a strong appetite for inspirational and educational events in this community.

"The range of presenters was excellent, it was so interesting to hear from people at all stages of their clinical/research career!"

- Allied health LACS symposium attendee, 2022

"Every talk was inspiring, there was a great selection of presenters." - LACS (medicine) symposium attendee, 2021

"I've realised that a clinician-scientist career pathway is realistic and that opportunities are on the horizon. I'm planning to seek out ways I can make this career path possible in my healthcare setting." - Allied health LACS event attendee, 2021



Mentorship program

The Academy's Mentorship Program aims to support the next generation of leaders in health and medical research. Emerging leaders can self-nominate or be nominated and successful candidates become Associate Members of the Academy for the three-year program. They receive targeted support from an AAHMS Fellow mentor, who offers an independent perspective and experienced advice for the duration. Mentees are admitted in two selection rounds annually.

"I have already recommended the program to several colleagues and two are now mentees!"

– Current mentee

"An excellent experience – both the individual mentor session and the broader network/workshop experiences." – Current Mentee

The Academy had 43 mentees participating in the program as of 30 June 2022 – 18 of these mentees were selected during 2020-21 financial year. They are:

- Associate Professor Pete
 Azzopardi, Adolescent Health Group
 Lead, Burnet and SAHMRI, VIC
- Associate Professor Lauren Ball, Principal Research Fellow (NHMRC Investigator) Griffith University, QLD
- Professor Tracy Burrows, Professor Nutrition and Dietetics, University of Newcastle, NSW
- Associate Professor James Chong, Cardiologist, Co-Director Centre for Heart Research, Westmead Hospital, Westmead Institute, University of Sydney, NSW
- Professor Tomas Kalincik, Head, Clinical Outcomes Research Unit; Head, MS Centre, University of Melbourne; Royal Melbourne Hospital, VIC
- Professor Chung Wei Christine Lin, Professorial Research Fellow, the University of Sydney, NSW
- Associate Professor Atul Malhotra, Associate Professor (Research), Monash University, VIC
- Professor Andrew Mallett, Director of Clinical Research and Nephrologist; Professor of Medicine, Townsville Hospital & Health Service and James Cook University (Conjoint), QLD
- Associate Professor Francine Marques, Associate Professor in Genetics and Genomics, Monash University, VIC

- Associate Professor Lisa Moran, Head, Healthy Lifestyle Research Program, National Heart Foundation Future Leader Fellow, Monash Centre for Health Research and Implementation, VIC
- Associate Professor Suzanne
 Nielsen, Deputy Director and
 NHMRC Career Development Fellow,
 Monash Addiction Research Centre,
 Monash University, VIC
- Associate Professor Claudia Nold, Group Head, Hudson Institute of Medical Research, VIC
- Professor Leanne Ooi, Principal Research Fellow, University of Wollongong, NSW
- Associate Professor Susanna Park, Associate Professor, University of Sydney, NSW
- Associate Professor Piero Perucca, Associate Professor or Adult Epilepsy, University of Melbourne, VIC
- Associate Professor David Scott, NHMRC Emerging Leadership Fellow, Deakin University, VIC
- Professor Anne Tiedermann, Principal Research Fellow, University of Sydney, NSW
- Doctor Nicola Waddell, Group Leader, QIMR Berghofer MRI, QLD

Honorific awards

The Academy has two awards specifically designed to nurture and celebrate talented individuals who are making significant contributions to furthering biomedical and health research, primarily working in Australia.





First awarded in 2020, the <u>Jian Zhou Medal</u> recognises rising stars of Australian health and medical science: individuals within 15 years of achieving their PhD (or equivalent first research higher degree) who is making a significant impact in translational medical science. The Jian Zhou Medal was made possible by a generous donation from the Frazer Family Foundation, for which the Academy is most grateful. In 2021 it was awarded to Professor Di Yu and Professor Sherene Loi FAHMS.



The Academy's <u>Medal for Outstanding Female Researcher</u> was established in 2020 to recognise women researchers who have made one or more ground-breaking discoveries in health and medical sciences. Consideration is given to individuals whose career has been interrupted, delayed or otherwise constrained through reasons including, but not limited to, illness, childbearing, childcaring or other caring responsibilities. The Academy appreciates the support of The Gandevia Foundation, whose generous donation made this award possible. The medal was awarded for the first time in September 2021 to Professor Georgina Long AO FAHMS.

Influencing policy

In 2021-22, the Academy has focused on three major policy priorities: harnessing research for better health, the health impacts of climate change and data-enabled research excellence. We also continued to provide advice to government in relation to the COVID-19 pandemic.

Additionally, the Academy has engaged in issues of national importance through responses to government consultations and inquiries including NHMRC consultation on options to reach gender equity, the Department of Health's Future-Focused Primary Healthcare 10-year plan, the Medical Research Future Fund strategy and priorities, feedback on the NHMRC draft guide for Research Integrity Advisors new draft guide. Details about the Academy's work on these policy priorities and submissions are available on the AAHMS policy webpage.

Harnessing research for better health

The Academy has continued to develop our major policy project – *Research and innovation as core functions in transforming the health system.* Chaired by Professor Christina Mitchell AO FAHMS, the project sets out a high-level vision for strategically embedding research, and its effective and efficient translation, into the health system to improve health outcomes for the community.

Throughout 2021 and early 2022, the working group consulted with more than 260 individuals from all eight states and territories across Australia and internationally, including healthcare professionals (across medicine, nursing, midwifery and allied health), researchers, research funders, senior healthcare executives, consumers, industry representatives, peak body representatives, charitable and philanthropic funders, government, Aboriginal and Torres Strait Islander researchers and individuals from rural and remote settings.

Following an extensive process of evidence collection and review of local and international data, the working group began to draft and develop findings into a report, which includes key recommendations for stakeholders in health, government, research and industry.

At June 30 2021, the final report was near completion. The report is expected to be published in October 2022 at the Academy's annual meeting.

The project's working group, made up of 15 of Australia's health and medical research sector leaders, provided experienced perspectives from across the sector, disciplines, specialities and professions to create the final report.

Project working group

- Chair: Professor Christina Mitchell AO FAHMS
- Dr Teresa Anderson AM
- Professor Jeffrey Braithwaite FAHMS
- Professor Michael Berk FAHMS
- Professor Jonathan Carapetis AM
- Professor Sandra Eades FASSA FAHMS
- Professor Ian Frazer AC FRS FAA FTSE FAHMS

- Professor Jane Gunn FAHMS
- Professor Caroline Homer AO FAHMS
- Associate Professor Sebastian King
- Professor Don Nutbeam FAHMS
- Scientia Professor Vlado Perkovic FAHMS
- Professor Claire Rickard FAHMS
- Professor Sir John Savill FRS FRSE FMedSci
- Professor Paul Scuffham FAHMS

Health impacts of climate change

In April 2021, the Academy published our statement on the health priority. The statement was the culmination of two years of evidence collection and review by the steering committee, led by co-chairs Professor Warwick Anderson, Professor Tony Capon and Professor Fran Baum. This included a series of sector discussions and roundtables focused on five areas: the Australian bushfires and impact on health; delivering fully sustainable healthcare; action on climate change and health; the health impacts of climate change; and climate change, health and First Nations knowledge practices.

A common theme across these meetings was that urgent action is necessary to address the causes of climate change, to mitigate the current and future threats to human health, and to monitor these dynamic risks and adaptations. As part of our statement, the Academy recognises that scientific evidence demands urgent action. A well-defined, quick, and staged path to a net-zero world is needed to ensure the health and wellbeing of all Australians.

The statement launched with an online event, chaired by project co-chair Professor Warwick Anderson FAHA FASSA FAHMS in discussion with Professor Ian Anderson AO FASSA FAHMS, Professor Peter Doherty AC FRS FAA FAHMS and Professor Fiona Stanley AC FASSA FAHMS (Hon). The event was well attended, with more than 280 registrants, and the statement launch was covered national media including AAP, *The Guardian, Cosmos, ABC Southern QLD radio, the Limbic* and *John Menadue's Public Policy Journal*.



Climate Change and Health Steering Committee

- Chair: Professor Warwick Anderson FAHA FASSA FAHMS (on leave August - October 2021)
- Professor Fran Baum AO FASSA FAHMS – (Acting Co-chair, August -October 2021)
- Professor Tony Capon (Acting Cochair, August - October 2021)
- Professor James McCarthy FAHMS
- Professor Tania Sorrell AM FAHMS

- Professor Ian Anderson AO FAHMS
- Professor Stephen Duckett FASSA FAHMS
- Professor Jane Fisher AO
- Associate Professor Coral Gartner
- Professor Billie Giles Corti
- Adjunct Professor Tarun Weeramanthri
- Professor Ingrid Scheffer (ex officio) AO FRS FAA PresAHMS

Data-enabled research excellence



The Academy worked alongside the nation's other Learned Academies, the Australian Council of Learned Academies (ACOLA) and the Australian Research Data Commons (ARDC) on <u>Australia's Data-Enabled Future</u> project.

This project combines the strategic knowledge and experience of the Learned Academies with the national data infrastructure of the ARDC to understand what tools and resources researchers need to advance data-enabled research, now and in the future.

Each of the Learned Academies have investigated data and infrastructure requirements within and between disciplines to identify common opportunities, challenges, priority and data gaps. AAHMS investigated these areas in the health and medical sciences led by our Health and Medical Data Steering Committee, which was chaired by Professor Louisa Jorm FAHMS. Our report, <u>Australia's Data-Enabled Research Future: Health and Medical Sciences</u>, was published in June 2022. This report explores the types of national datasets accessed and used for health and medical research, how these are used by the sector, and outlines the strategic infrastructure needs and requirements for health and medical research data.

AAHMS' findings contributed to a <u>multidiscipline</u>, <u>collaborative report</u>, coordinated by ACOLA, that outline how best Australia could support researchers to address society's greatest challenges.

We also made a <u>submission to the Federal Government's Australian Data Strategy</u> <u>consultation</u>, based on the findings of our report.

Health and Medical Data Steering Committee

- Chair Professor Louisa Jorm FAHMS
- Professor Melanie Bahlo FAHMS
- Professor Julie Byles AO FAHMS
- Professor John Carlin FAHMS
- Professor Annette Dobson AM FAHMS
- Professor Stephen Jan FAHMS
- Professor Anton Peleg FAHMS

Governance

Academy Executive and Council (2021-22)

The Executive (Board)



Professor Ingrid Scheffer AO FRS FAA PresAHMS President (2019 -), Director (2014 -)



Professor Bronwyn Kingwell FAHMS Director (2017 -)



Professor Simon Foote FAA FTSE FAHMS Hon. Treasurer and Public Officer (2017 –), Director (2014 –)



Professor Robyn Ward AM FAHMS Director (2014 –)




Professor Ian Frazer AC FRS FAA FTSE FAHMS Immediate Past President (2019 -), Director (2014 -)



Professor Kathryn North AC FAHMS Director (2020 -)



Professor Steven Wesselingh FAHMS President-elect (2021-), Director (2014 -)





Professor Anthony Cunningham AO FAHMS Chair, NSW & ACT State Branch (2019 -)



Professor Maria Makrides FAA FAHMS Chair, SA & NT State Branch (2019 -)



Professor Flavia Cicuttini FAHMS Chair, VIC & TAS (2021 -)



Professor David Whiteman AM FAHMS Chair, QLD State Branch (2019 -)



Professor David Mackay AO FAHMS Chair, WA State Branch (2018 –)

Ordinary Council Members



Professor Gabrielle Belz FAHMS Council Member (2020 -)



Professor Frank Gannon FAHMS Council Member (2016 -)



Professor Susan Davis AO FAHMS Council Member (2021 -)



Professor John Kaldor FAHMS Council Member (2020 -)



Distinguished Professor Elizabeth Elliott FAHMS Council Member (2020 -)



Professor Fabienne Mackay FAHMS Council Member (2020 -)



Professor Simon Gandevia FAA FAHMS Council Member (2017 -)



Professor Paul Scuffham FAHMS Council Member (2019 -)

Standing Committees (2021-22)

Finance, Audit and Risk Committee

Honorary Treasurer: Professor Simon

Foote (Chair)

Professor David Adams

Professor Louise Baur

Professor Ian Frazer

Professor Stephen Nicholls

Professor Andrew Scott

Professor Lezanne Ooi

Professor Ingrid Scheffer (ex officio)

Mentorship Committee

Professor Louise Baur (Chair)

Professor Tim Hughes

Professor Christina Mitchell

Professor Claire Rickard

Professor Maree Teesson

Professor Louise Maple-Brown

Professor David Mackey

Professor Steve Webb

Professor Ingrid Scheffer (ex officio)

Policy Advice Committee

Professor Frank Gannon (Chair)

Professor Melanio Bahlo

Associate Professor Lauren Ball

Professor John Carlin

Professor Elizabeth Elliott

Professor Simon Gandevia

Professor Louisa Jorm

Professor Dianne Nicol

Professor Don Nutbeam

Professor Paul Scuffham

Associate Professor Susanna Park

Professor Ingrid Scheffer (ex officio)

Secretariat (July 2021 - June 2022)

Chief Executive Officer (on parental leave from March 2021 - October 2021)

Catherine Luckin

Interim Chief Executive Officer (from March 2021 - October 2021)

Dr Cath Latham

Policy Manager (until February 2022)

Dr Amanda Rush

Policy Manager (from March 2022, Policy Officer prior to this date)

Lanika Mylvaganam

Policy Officer (March - June 2022)

Katrin Forslund

Policy Officer (from June 2022)

Emily Todd

Programs and Events Manager (from March 2021-March 2022)

Thy Boskovic

Programs and Events Manager (parental leave cover November 2021- April 2022) Ida Gambaro

Programs and Events Manager (from May 2022)

Claire Vaz

Communication and Media Engagement Manager (on parental leave from March 2022)

Katie Rowney


Communication and Media Engagement Manager (parental leave cover from March 2022)

Margaret de Silva

Senior Fellowship, Awards and Administration Coordinator

Dr Carla Muma

Organisational chart (2021-22)



Financials

Treasurer's report

The Academy has reported a surplus of \$236,362 (2021 surplus was \$111,395) for the financial year ending 30 June 2022 and is solvent.

As in previous years, Fellows' subscriptions were a key source of income. We also received the second grant in aid in recognition of AAHMS status as one of Australia's five Learned Academies. This ongoing financial support is provided by the Australian Government through the Department of Education's Higher Education Research Promotion (HERP) scheme and has made a significant difference to the financial outlook for the Academy. Combined with the support from Fellows' subscriptions, this grant has ensured that the Academy can continue to assist with Australia's national response to emergencies, such as bushfires and the pandemic, and to build policy efforts addressing strategic priorities – the impacts of climate change on health and the need for evidence-based healthcare. On behalf of the Executive, I would like to thank Fellows for their support and input to deliver on our mission and purpose over the past 12 months.

The Executive has maintained Fellowship fees at the same rate since 2020. The Executive, taking advice from the Finance, Audit and Risk Committee, has agreed to increase Fellowship fees by 2% in the next financial year. Standard Fellowship fees for 2022/23 will therefore rise to \$1,339 (including GST), with other fees adjusted accordingly.

Although investment income continues to be relatively modest, the Executive has resolved to maintain a low-risk and short-term investment strategy for the coming financial year and will reassess this strategy regularly, in liaison with the Finance, Audit and Risk Committee.

The Academy's secretariat is now 5.6 FTE, which has enabled the continuation of the increase in activities seen as a result of our first year of the HERP grant last year, which allow us to deliver towards the Academy's strategic objectives.

Balances as of 30 June 2022:

Total Equity = A\$ 1,274,923

Income from Memberships = A\$ 397,833

Total Operating Costs for YTD ending 30 June = A\$ 949,796

For a more detailed breakdown of income and expenditure please refer to the AAHMS General Purpose Financial Report below for the year ending 30 June 2022.

I am grateful for the support provided by members of the Finance, Risk and Audit Committee. I look forward to another strong and productive year.

Professor Simon Foote FAA FTSE FAHMS

Hon Treasurer 2018 -

Financial Statements	
For the year ended 30 June 2022	
Tor the year chided 30 Julie 2022	
	Annual Report June 2022 Page 21

Financial Statements

For the Year Ended 30 June 2022

Contents

For the Year Ended 30 June 2022

	Page
Financial Statements	
Auditor's Independence Declaration under Section 307C of the Corporations Act 2001	1
Statement of Profit or Loss and Other Comprehensive Income	2
Statement of Financial Position	3
Statement of Changes in Equity	4
Statement of Cash Flows	5
Notes to the Financial Statements	6
Directors' Declaration	14
Independent Audit Report	15



AUSTRALIAN ACADEMY OF HEALTH AND MEDICAL SCIENCES LTD ABN 55 167 124 067

AUDITOR'S INDEPENDENCE DECLARATION UNDER SUBDIVISION 60-C SECTION 60-40 OF THE AUSTRALIAN CHARITIES AND NOT-FOR-PROFITS COMMISSION ACT 2012 TO THE DIRECTORS OF AUSTRALIAN ACADEMY OF HEALTH AND MEDICAL SCIENCES LTD

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2022 there have been:

- I. no contraventions of the auditor independence requirements as set out in the *Australian Charitie and Not-for-profits Commission Act 2012* in relation to the audit; and
- II. no contraventions of any applicable code of professional conduct in relation to the audit.

C.w. stuly %o

CW STIRLING & CO Chartered Accountants

for A Pholy

John A Phillips Partner

Dated this 16th day of September 2022 Melbourne, Victoria

Statement of Profit or Loss and Other Comprehensive IncomeFor the Year Ended 30 June 2022

		2022	2021
	Note	\$	\$
Revenue	4	397,833	376,975
Finance income		1,281	1,306
Other income	4	787,044	412,331
Employee benefits expense		(736,444)	(511,126)
Depreciation and amortisation expense		-	(53)
Other expenses		(213,352)	(168,038)
Profit before income tax		236,362	111,395
Income tax expense		-	
Total comprehensive income for the			
year	_	236,362	111,395

Statement of Financial Position

As At 30 June 2022

	Note	2022 \$	2021 \$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	6	1,395,956	1,309,305
Trade and other receivables	7	46,053	23,836
Inventories	9	46,800	30,000
Other assets	8 _	18,897	1,000
TOTAL CURRENT ASSETS	_	1,507,706	1,364,141
NON-CURRENT ASSETS	_		
TOTAL ASSETS	_	1,507,706	1,364,141
LIABILITIES			
CURRENT LIABILITIES	4.4	05.047	00.040
Trade and other payables	11	65,617	36,919
Employee benefits Other liabilities	13 12	38,862 125,878	28,004 260,657
TOTAL CURRENT LIABILITIES	12 –	230,357	325,580
NON-CURRENT LIABILITIES	_	230,337	323,360
Employee benefits	13	2,426	_
TOTAL NON-CURRENT LIABILITIES		2,426	
TOTAL LIABILITIES		232,783	325,580
NET ASSETS		1,274,923	1,038,561
EQUITY			
Reserves	14	236,362	-
Retained earnings	_	1,038,561	1,038,561
	_	1,274,923	1,038,561
TOTAL EQUITY	_	1,274,923	1,038,561

Statement of Changes in Equity

For the Year Ended 30 June 2022

2022

	Note	Retained Earnings \$	General Reserve \$	Total \$
Balance at 1 July 2021	Note	1,038,561	<u> </u>	1,038,561
Profit attributable to members of the entity		236,362	<u>-</u>	236,362
Transfers from retained earnings to general reserve	14	(236,362)	236,362	_
Balance at 30 June 2022		1,038,561	236,362	1,274,923
2021		Retained Earnings		Total
	Note	\$	\$	\$
Balance at 1 July 2020		942,825	<u> </u>	942,825
Restatement due to adoption of AASB 119		(15,659)	-	(15,659)
Balance at 1 July 2020 restated		927,166	-	927,166
Profit attributable to members of the entity		111,395	-	111,395
Balance at 30 June 2021		1,038,561	-	1,038,561

Statement of Cash Flows

For the Year Ended 30 June 2022

	Note	2022 \$	2021 \$
CASH FLOWS FROM OPERATING ACTIVITIES:			
Receipts from customers		1,027,881	1,038,746
Payments to suppliers and employees		(942,511)	(661,323)
Interest received	_	1,281	1,306
Net cash provided by/(used in) operating activities	20	86,651	378,729
CASH FLOWS FROM INVESTING ACTIVITIES:			
Net increase/(decrease) in cash and		00.054	270 700
cash equivalents held		86,651	378,729
Cash and cash equivalents at beginning of year		1,309,305	930,576
Cash and cash equivalents at end of financial year	6	1,395,956	1,309,305

Notes to the Financial Statements

For the Year Ended 30 June 2022

The financial report covers Australian Academy of Health and Medical Sciences Limited as an individual entity. Australian Academy of Health and Medical Sciences Limited is a not-for-profit Company limited by guarantee, incorporated and domiciled in Australia.

The functional and presentation currency of Australian Academy of Health and Medical Sciences Limited is Australian dollars.

The financial report was authorised for issue by the Directors on 01 September 2022.

Comparatives are consistent with prior years, unless otherwise stated.

1 Basis of Preparation

The financial statements are general purpose financial statements that have been prepared in accordance with the Australian Accounting Standards - Simplified Disclosures and the Australian Charity and Not-for-profits Commission Act 2012

The financial statements have been prepared on an acruals basis and are based on historical costs.

2 Summary of Significant Accounting Policies

(a) Revenue and other income

Grant revenue

Government grants are recognised at fair value where there is reasonable assurance that the grant will be received and all grant conditions will be met. Grants relating to expense items are recognised as the expenditure is incurred. Grants relating to assets are credited to deferred income at fair value and are credited to income over the expected useful life of the asset on a straight-line basis.

Other income

Other income is recognised on an accruals basis when the Company is entitled to it.

(b) Income Tax

The company is excempt from income tax under Division 50 of the Income Tax Assessment Act 1997.

(c) Goods and services tax (GST)

Revenue, expenses and assets are recognised net of the amount of goods and services tax (GST), except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

Receivables and payable are stated inclusive of GST.

Cash flows in the statement of cash flows are included on a gross basis and the GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation authority is classified as operating cash flows.

Notes to the Financial Statements

For the Year Ended 30 June 2022

2 Summary of Significant Accounting Policies

(d) Inventories

Inventories are measured at the lower of cost and net realisable value.

Inventories acquired at no cost, or for nominal consideration are valued at the current replacement cost as at the date of acquisition, which is the deemed cost.

(e) Property, plant and equipment

Each class of property, plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation and impairment.

Plant and equipment

Plant and equipment are measured using the cost model.

Depreciation

Property, plant and equipment, excluding freehold land, is depreciated on a reducing balance basis over the assets useful life to the Company, commencing when the asset is ready for use.

At the end of each annual reporting period, the depreciation method, useful life and residual value of each asset is reviewed. Any revisions are accounted for prospectively as a change in estimate.

(f) Financial instruments

Financial instruments are recognised initially on the date that the Company becomes party to the contractual provisions of the instrument.

On initial recognition, all financial instruments are measured at fair value plus transaction costs (except for instruments measured at fair value through profit or loss where transaction costs are expensed as incurred).

Financial assets

All recognised financial assets are subsequently measured in their entirety at either amortised cost or fair value, depending on the classification of the financial assets.

The Company's financial assets measured at amortised cost comprise trade and other receivables and cash and cash equivalents in the statement of financial position.

Subsequent to initial recognition, these assets are carried at amortised cost using the effective interest rate method less provision for impairment.

Trade receivables and contract assets

Impairment of trade receivables and contract assets have been determined using the simplified approach in AASB 9 which uses an estimation of lifetime expected credit losses. The Company has determined the probability of non-payment of the receivable and contract asset and multiplied this by the amount of the expected loss arising from default.

Notes to the Financial Statements

For the Year Ended 30 June 2022

2 Summary of Significant Accounting Policies

(f) Financial instruments

Financial assets

The amount of the impairment is recorded in a separate allowance account with the loss being recognised in finance expense. Once the receivable is determined to be uncollectable then the gross carrying amount is written off against the associated allowance.

Financial liabilities

The Company measures all financial liabilities initially at fair value less transaction costs, subsequently financial liabilities are measured at amortised cost using the effective interest rate method.

The financial liabilities of the Company comprise trade payables, bank and other loans and lease liabilities.

(g) Impairment of non-financial assets

At the end of each reporting period the Company determines whether there is an evidence of an impairment indicator for non-financial assets.

Where the recoverable amount is less than the carrying amount, an impairment loss is recognised in profit or loss.

(h) Cash and cash equivalents

Cash and cash equivalents comprises cash on hand, demand deposits and short-term investments which are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

(i) Employee benefits

Provision is made for the Company's liability for employee benefits arising from services rendered by employees to the end of the reporting period. Employee benefits that are expected to be wholly settled within one year have been measured at the amounts expected to be paid when the liability is settled, plus related oncosts.

3 Critical Accounting Estimates and Judgments

The directors make estimates and judgements during the preparation of these financial statements regarding assumptions about current and future events affecting transactions and balances.

These estimates and judgements are based on the best information available at the time of preparing the financial statements, however as additional information is known then the actual results may differ from the estimates.

The significant estimates and judgements made have been described below.

Key estimates - receivables

The receivables at reporting date have been reviewed to determine whether there is any objective evidence that any of the receivables are impaired. An impairment provision is included for any receivable where the entire balance is not considered collectible. The impairment provision is based on the best information at the reporting date.

Notes to the Financial Statements

For the Year Ended 30 June 2022

4 Revenue and Other Income

5

6

7

Revenue from continuing operations			
		2022	2021
		\$	\$
Revenue from other sources		227 222	070.075
- member subscriptions	-	397,833	376,975
Total Revenue	_	397,833	376,975
		2022 \$	2021 \$
Other Income		Ψ	Ψ
Other Income - Government assistance (COVID 19)		-	118,550
- events and other		48,849	3,802
- sponsorship		39,905	38,636
- donations		9,011	12,000
- Grants - Commonwealth recurrent	12	639,279	239,343
- Other grants	_	50,000	
	_	787,044	412,331
Result for the Year			
The result for the year includes the following specific expenses:			
Employee benefits expense		736,444	511,126
Depreciation expense		-	53
Cash and Cash Equivalents			
		2022	2021
Dealthalanasa		\$ 4.205.050	\$ 4.200.205
Bank balances	-	1,395,956	1,309,305
	=	1,395,956	1,309,305
Trade and Other Receivables			
		2022	2021
		\$	\$
CURRENT			
Trade receivables		52,053	29,335
Provision for impairment	_	(6,000)	(5,499)
Total current trade and other receivables		46,053	23,836
	=	-,	,

The carrying value of trade receivables is considered a reasonable approximation of fair value due to the short-term nature of the balances.

Notes to the Financial Statements

For the Year Ended 30 June 2022

8	Other Assets		
		2022	2021
		\$	\$
	CURRENT	40.007	4 000
	Prepayments	18,897	1,000
		18,897	1,000
9	Inventories		
9	inventories	2022	2021
		\$	\$
	CURRENT		
	At cost:		
	Merchandise	46,800	30,000
		46,800	30,000
10	Property, plant and equipment		
	PLANT AND EQUIPMENT		
	Office equipment		
	At cost	13,799	13,799
	Accumulated depreciation	(13,799)	(13,799)
	Computer equipment		47.050
	At cost Accumulated depreciation	<u>-</u>	17,850 (17,850)
	Total		
	Total	-	-
11	Trade and Other Payables		
	CURRENT		
	GST payable	17,876	10,386
	Trade payables and accrued expenses	47,741	26,533
		65,617	36,919

Notes to the Financial Statements

For the Year Ended 30 June 2022

12 Other liabilities	s
----------------------	---

	Income in advance opening balance	260,657	<u>-</u>
	Grant received	504,500	500,000
	Carried forward to Income in	,	,
	advance	(125,878)	(260,657)
	Total grant taken to income	639,279	239,343
13	Employee Benefits		
		2022	2021
		\$	\$
	Current liabilities		
	Provision for employee benefits	38,862	28,004
		38,862	28,004
	Mary suggests Pale TPC as		· · · · · · · · · · · · · · · · · · ·
	Non-current liabilities Provision for employee benefits	2,426	
	Provision for employee benefits		
		2,426	
14	Reserves		
		2022	2021
		\$	\$
	General reserve		
	Opening balance	-	-
	Transfers in	236,362	-
	Total	236,362	

The General Reserve sets aside funds from profits for future commitments and the company's financial projects.

15 Members' Guarantee

The Company is incorporated under the *Corporations Act 2001* and is a Company limited by guarantee. If the Company is wound up, the constitution states that each member is required to contribute a maximum of \$ 10 each towards meeting any outstandings and obligations of the Company. At 30 June 2022 the number of members was 448 (2021: 418).

Notes to the Financial Statements

For the Year Ended 30 June 2022

16 Key Management Personnel Remuneration

The totals of remuneration paid to the key management personnel of Australian Academy of Health and Medical Sciences Limited during the year are as follows:

	2022	2021
	\$	\$
Short-term employee benefits	248,526	228,630
Total	248,526	228,630

There were no transactions with related parties during the year, apart from a Director being reimbursed \$469 for costs incurred on behalf of the company.

17 Auditors' Remuneration

	2022	2021
	\$	\$
Merrotts Chartered Accountants		
- auditing or reviewing the		
financial statements	=	10,000
- other services	10,500	3,500
CW Stirling & Co Chartered		
Accountants		
- auditing or reviewing the	40.000	
financial statements	10,000	
Total	20,500	13,500

18 Contingencies

Contingent Liabilities

Australian Academy of Health and Medical Sciences Limited had the following contingent liabilities at the end of the reporting period:

The company has committed to holding an annual general meeting and Gala dinner on 13th October 2022. The total cost of the event is estimated to be in the order of \$115,000 with at least \$100,000 to be sought to be recovered from participants.

As at 30 June 2022, actual agreements in place for non-refundable commitments by AAHMS were estimated to be \$10,814 of which \$4,690 had been paid.

19 Right-of-use lease assets

The company has entered two leases of office space to assist in meeting its charitable objectives. The lease commitments are substantially below market rates. The lease at University of Sydney expires on 31 December 2022 and payments are \$1 per year. The lease in Brisbane has payments of \$1 per year. As a not-for-profit charity, the company accounts for the Right-of-use lease assets at cost.

Notes to the Financial Statements

For the Year Ended 30 June 2022

20 Cash Flow Information

(a) Reconciliation of result for the year to cashflows from operating activities

Reconciliation of profit to net cash provided by operating activities:

2022	2021
\$	\$
236,362	111,394
=	53
501	2,999
(22,719)	(3,967)
(34,697)	12,135
28,698	(9,638)
(134,779)	253,406
13,285	12,347
86,651	378,729
	\$ 236,362 - 501 (22,719) (34,697) 28,698 (134,779) 13,285

21 Events Occurring After the Reporting Date

The financial report was authorised for issue on 16 September 2022 by the board of directors.

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.

22 Statutory Information

The registered office and principal place of business of the company

Gabba Towers

411 Vulture St

Woollangabba 4102

Directors' Declaration

The responsible persons declare that in the responsible persons' opinion:

- There are resonable grounds to believe that the company is able to pay its debts as and when they become due and
 payable.
- The financial statements and notes satisfy the requirements of the Australian Charities and Not-for-profit Commission Act 2012.

Signed on behalf of all Responsible Persons by resolution of the Board in accordance with subsection 60.15(2) of the Australian Charities and Not-for-profits Commission Regulation 2013.

	φ	00	
	\sim		
Director			

Fonto

Dated 16 September 2022



AUSTRALIAN ACADEMY OF HEALTH AND MEDICAL SCIENCES LTD ABN 55 167 124 067

INDEPENDENT AUDIT REPORT TO THE MEMBERS OF AUSTRALIAN ACADEMY OF HEALTH AND MEDICAL SCIENCES LTD

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of the Australian Academy of Health and Medical Sciences Ltd, which comprises the statement of financial position as at 30 June 2022, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors declaration.

In our opinion the accompanying financial report of the Australian Academy of Health and Medical Sciences Ltd has been prepared in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (a) giving a true and fair view of the company's financial position as at 30 June 2022 and of its financial performance for the year then ended; and
- (b) complying with Australian Accounting Standards AASB: 1060 General Purpose Financial Statements Simplified Disclosures for For-Profit and Not-for-Profit Tier 2 Entities and Division 60 of the Australian Charities and Not-for-profits Commission Regulation 2013.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the company in accordance with the ACNC Act, the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Directors for the Financial Report

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards – AASB: 1060 General Purpose Financial Statements - Simplified Disclosures for For-Profit and Not-for-Profit Tier 2 Entities and the Australian Charities and Not-for-profits Commission Act 2012 and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.



AUSTRALIAN ACADEMY OF HEALTH AND MEDICAL SCIENCES LTD ABN 55 167 124 067

INDEPENDENT AUDIT REPORT TO THE MEMBERS OF AUSTRALIAN ACADEMY OF HEALTH AND MEDICAL SCIENCES LTD

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that
 are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
 effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by directors.
- Conclude on the appropriateness of the director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

C.w. study 860

C.W. Stirling & Co. Chartered Accountants

for A Pholy

John A Phillips Partner

Dated this 16th day of September 2022 Melbourne.



ABN 55 167 124 067 Gabba Towers, 411 Vulture Street, Woolloongabba, QLD 4102 PO Box 6114 Woolloongabba, QLD 4102 tel.: +61 (0) 7 3102 7220 email: CEO@aahms.org aahms.org